NaturalShrimp Announces Filing of Joint Patent Application
NaturalShrimp Announces Filing of Joint Patent Application
Strengthens Intellectual Property (IP) Protection Related to Electrocoagulation (EC) and HydroGas Technologies
加強與電凝聚(EC)和氫氣技術相關的知識產權(IP)保護
DALLAS, TX, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), and its technology partner, Hydrenesis, Inc., today announced the filing a United States joint patent application to further strengthen the Intellectual
達拉斯，德克薩斯州，2022年10月6日(Global Newswire)--Via NewMediaWire-NaturalShrimp，Inc.(OTCQB：SHMP)是一家生物技術水產養殖公司，已經開發並獲得了第一個以蝦為中心的商業操作RAS(循環水產養殖系統)並獲得了專利，它的技術合作夥伴Hydrenesis，Inc.今天宣佈提交一項美國聯合專利申請，以進一步加強對蝦的智力
Property (IP) protection related to Electrocoagulation (EC) and HydroGas technologies.
與電凝聚(EC)和氫氣技術相關的財產(IP)保護。
EC and Hydrogas have shown efficacy in improving welfare scores not only in shrimp production, but also in finfish, as evidenced by third party trials conducted at a leading aquaculture testing facility in Bergen, Norway. The newly filed patent application involves technology co-developed by NaturalShrimp and Hydrenesis as a strategy to augment existing IP protection with additional, and more advanced methods and apparatus. NaturalShrimp will license the EC and HydroGas technologies for various aquatic species.
歐共體和氫化氣不僅在對蝦生產方面，而且在在挪威卑爾根的一家領先的水產養殖測試設施進行的第三方試驗中，都顯示出提高福利分數的有效性。新提交的專利申請涉及NaturalShrimp和Hydrenesis共同開發的技術，作為一種戰略，用更多和更先進的方法和設備來加強現有的知識產權保護。NaturalShrimp將為各種水生物種授權EC和Hapor Gas技術。
"We are constantly looking for ways to improve efficiency and broad applications for our technologies, not just in shrimp, but also in additional aquatic species," said Tom Untermeyer, Chief Operations Officer and Chief Technology Officer. "Our work with Hydrenesis to develop the new technologies has strengthened our engineering capabilities, and we look forward to ongoing co-development work with Hydrenesis to enhance our IP portfolio even further."
首席運營官兼首席技術官湯姆·昂特邁爾説，我們一直在尋找提高效率的方法，並將我們的技術廣泛應用於其他水生物種，不僅是蝦，還有其他水生物種。我們與Hydrenesis公司合作開發新技術增強了我們的工程能力，我們期待着與Hydrenesis公司繼續共同開發工作，以進一步增強我們的知識產權組合。“
Gerald Easterling, Chief Executive Officer, added, "As we continue to expand our shrimp production capabilities, having additional IP such as this will only strengthen our presence both domestically and internationally, as we expand over the next several years."
首席執行官傑拉爾德·伊斯特林補充説：“隨着我們繼續擴大我們的對蝦生產能力，擁有這樣的額外知識產權只會加強我們在國內和國際上的存在，因為我們將在未來幾年擴大規模。”
David Antelo, Hydrenesis President and CEO, also added, "The cohesive relationship between the NaturalShrimp and Hydrenesis engineering teams has accelerated the development of our technologies as we focus on an aggressive growth trajectory. This joint patent represents more than 12 months of collaboration and is expected to add shareholder value as the commercialization phases unfold."
Hydrenesis總裁首席執行官兼首席執行官戴維·安特洛也補充道：“NaturalShrimp和Hydrenesis工程團隊之間的緊密聯繫加速了我們技術的發展，因為我們專注於積極的增長軌跡。這項聯合專利代表着12個多月的合作，隨着商業化階段的展開，預計將增加股東價值。”
About NaturalShrimp
關於天然蝦
NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. For more information visit .
NaturalShrimp，Inc.是一家上市水產養殖公司，總部設在達拉斯，生產設施位於德克薩斯州聖安東尼奧和愛荷華州韋伯斯特市附近。該公司開發了第一個商業上可行的系統，用於在封閉的鹹水系統中種植蝦，使用專利技術生產新鮮的、從未冷凍的自然生長的蝦，而不使用抗生素或有毒化學品。NaturalShrimp系統可以分佈在世界任何地方，生產美食級的太平洋白蝦。有關更多信息，請訪問。
Forward-Looking Statements
前瞻性陳述
This press release contains a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021, any of which may cause our company's or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
本新聞稿包含許多前瞻性陳述，反映管理層對未來事件和財務業績的當前看法。前瞻性陳述是對未來事件或我們未來財務表現的預測。在某些情況下，您可以通過“可能”、“應該”、“預期”、“計劃”、“預期”、“相信”、“估計”、“預測”、“可能”或“繼續”等術語或這些術語或其他類似術語的負面含義來識別前瞻性陳述。這些陳述包括關於我們和我們管理團隊成員的意圖、信念或當前期望的陳述，以及此類陳述所基於的假設。提醒潛在投資者，任何此類前瞻性陳述都不是對未來業績的保證，涉及風險和不確定因素，實際結果可能與此類前瞻性陳述中預期的大不相同。這些陳述只是預測，涉及已知和未知的風險、不確定因素和其他因素，包括公司在截至2021年3月31日的財政年度的10-K表格年度報告中“風險因素”一節所闡述的風險，任何這些風險都可能導致我們公司或我們行業的實際結果、活動水平、業績或成就與我們的前瞻性陳述中明示或暗示的任何未來結果、活動水平、表現或成就大不相同。
Investor Relations Contact
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
SHMP@mzgroup.us
投資者關係聯繫人
克里斯·泰森
總裁常務副總經理
MZ北美
直撥：949-491-8235
郵箱：shmp@mzgroup.us
譯文內容由第三人軟體翻譯。